Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
A Randomized, Multicentre Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Proxinium Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Advanced SCCHN Who Have Received at Least One Anti-cancer Treatment Regimen for Advanced Disease
Sponsor: Sesen Bio, Inc.
This PHASE2/PHASE3 trial investigates Carcinoma, Squamous Cell and Carcinoma, Squamous Cell of Head and Neck and is currently terminated or withdrawn. Sesen Bio, Inc. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sesen Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Astrakhan, Russia , Bahía Blanca, Argentina , Bangalore, India , Banská Bystrica, Slovakia , Barcelona, Spain , Barretos, Brazil , Beersheba, Israel , Belgrade, Serbia , Berlin, Germany , Brasília, Brazil and 88 more locations